2 Information about relugolix–estradiol–norethisterone acetate

Marketing authorisation indication

2.1 Relugolix–estradiol–norethisterone acetate (Ryeqo, Gedeon Richter UK) is indicated for the 'treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age'.

Dosage in the marketing authorisation


2.3 The list price of relugolix–estradiol–norethisterone acetate is £72.00 for a 28‑pack of 40 mg/1 mg/0.5 mg tablets (excluding VAT; BNF online, accessed April 2022). The annual treatment cost is £939.21. Costs may vary in different settings because of negotiated procurement discounts.

  • National Institute for Health and Care Excellence (NICE)